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Objective To assess the status of type 2 diabetes care 
in general practice and changes in the quality of care 
between 2005 and 2014, and to identify areas of diabetes 
care requiring improvement.
Research design and methods Two cross-sectional 
surveys were performed that included patients with type 
2 diabetes in selected areas (n=9464 in 2014, n=5463 
in 2005). Quality of care was assessed based on key 
recommendations in national guidelines. Differences 
in clinical performance between 2005 and 2014 were 
assessed in regression models adjusting for age, sex, 
counties and clustering within general practices.
Results Treatment targets were achieved in a higher 
proportion of patients in 2014 compared with 2005: 
hemoglobin A1c ≤7.0% (≤53 mmol/mol) in 62.8% vs 
54.3%, blood pressure ≤135/80 mm Hg in 44.9% vs 
36.6%, and total cholesterol ≤4.5 mmol/L in 49.9% 
vs 33.5% (all adjusted P≤0.001). Regarding screening 
procedures for microvascular complications, fewer patients 
had recorded an eye examination (61.0% vs 71.5%, 
adjusted P<0.001), whereas more patients underwent 
monofilament test (25.9% vs 18.7%, adjusted P<0.001). 
Testing for albuminuria remained low (30.3%) in 2014. A 
still high percentage were current smokers (22.7%).
Conclusions We found moderate improvements in risk 
factor control for patients with type 2 diabetes in general 
practice during the last decade, which are similar to 
improvements reported in other countries. We report major 
gaps in the performance of recommended screening 
procedures to detect microvascular complications. The 
proportion of daily smokers remains high. We suggest 
incentives to promote further improvements in diabetes 
care in Norway.
InTROduCTIOn
Good glycemic control and appropriate 
management of cardiovascular risk factors in 
patients with type 2 diabetes reduce the risk of 
vascular complications and mortality.1–9 The 
Steno-2 trial found an increase in lifespan in 
high-risk patients with type 2 diabetes with 
a combined behavioral and pharmacolog-
ical intervention in a specialist care setting.5 
However, in most countries the majority of 
patients with type 2 diabetes are treated in 
primary care. The initial 5-year follow-up of 
the Anglo-Danish-Dutch Study of Intensive 
Treatment in People with Screen Detected 
Diabetes in Primary Care (ADDITION-Eu-
rope) trial of screening-detected patients 
with type 2 diabetes in general practice found 
improved risk factor levels and a trend toward 
a reduced rate of cardiovascular events, 
microvascular complications and death in 
the multifactorial treatment group compared 
significance of this study
What is already known about this subject?
 ► Adequate control of cardiovascular risk factors and 
the early detection of microvascular complications 
may prevent or delay the development of 
complications in type 2 diabetes.
What are the new findings?
 ► We found moderate improvements in blood 
pressure and lipid control between 2005 and 2014, 
but the performance of screening procedures for 
microvascular complications remained poor.
How might these results change the focus of 
research or clinical practice?
 ► The results should increase doctors’ awareness of 
the importance of risk factor control and the early 
detection of microvascular complications, and 
may encourage the authorities to create systems 
that can help general practitioners to implement 
guideline recommendations.
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Figure 1 Flow chart of general practices and patients with 
diabetes included in the Rogaland-Oslo-Salten-Akershus-
Hordaland study (ROSA 4) in 2014. GP, general practitioner; 
MODY, maturity onset diabetes of the young.
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with routine care.10 11 A Swedish observational study with 
13 000 patients with type 2 diabetes from general prac-
tice in 2012 reported that fatal and non-fatal cardiovas-
cular disease (CVD) decreased from 23.6% to 6.0% when 
they compared patients achieving a decrease versus an 
increase in hemoglobin A1c (HbA1c), blood pressure 
and lipids.4 It has also been shown that early detection 
of complications by systematic screening and interven-
tion prevents or delays the development of target organ 
disease.12 13
Risk factor control and screening for early complica-
tions can only be closely monitored in countries with 
nationwide and comprehensive diabetes registries such as 
Sweden and Scotland.14 15 Other countries must perform 
cross-sectional surveys to assess status and time trends in 
diabetes care.16–19 In Norway, the quality of type 2 diabetes 
care has been assessed through repeated cross-sec-
tional surveys (Rogaland-Oslo-Salten-Akershus-Horda-
land (ROSA) studies) since 1995. The previous survey, 
ROSA 3, was performed in 2005 and showed substantial 
improvements in glycemic, blood pressure and lipid 
control between 1995 and 2005.20 21
A new assessment of the quality of diabetes care was 
important for several reasons.
First, several new glucose-lowering agents have been 
approved since 2005, and antihyperglycemic drug expen-
diture has increased by approximately 60% in Norway 
and the USA.22 23 Second, during the last decade several 
large studies comparing different treatment targets for 
diabetes have failed to show additional benefit from 
extremely intensive treatment targets.24–26 As a result 
of these studies modern diabetes guidelines emphasize 
the importance of individual treatment targets that may 
influence the overall quality of care.27–29 Finally, Norway 
offers government-funded healthcare services to all 
inhabitants, and these services are expected to provide 
high-quality diabetes care. We therefore designed a large 
cross-sectional survey in 2014, the ROSA 4 study, with the 
objective of assessing the current status of type 2 diabetes 
care in general practice and changes in the quality of 
care between 2005 and 2014, and identifying areas of 
care requiring improvement.
ReseaRCH desIgn and meTHOds
ROSA 4 is a population-based cross-sectional survey 
designed to assess the quality of care of patients with 
type 2 diabetes in general practice in Norway in 2014. We 
included patients with diabetes living in urban and rural 
areas in 5 of 19 counties, covering more than 50% of 
the general population in Norway. General practitioners 
(GPs) in these areas were invited to participate, and 77 
practices (73% of the invited) with 282 GPs (77% of the 
invited) agreed (figure 1). Data were collected from the 
electronic patient records from all the GPs within a prac-
tice by research nurses.
All adults (≥18 years) with a diagnosis of diabetes (T89 
and T90 in the International Classification of Primary 
Care) between 2012 and 2014 were identified using 
customized software that also captured predefined data 
from the electronic patient records. The records were 
examined manually by research nurses to verify elec-
tronically registered data and to collect data not suit-
able for electronic capture. Data capture was performed 
in January 2015–April 2016.
The following variables were registered in the survey: 
patient characteristics (age, sex, ethnicity, diabetes 
duration, height and weight, smoking status); processes 
of care (documentation of HbA1c, blood pressure, 
lipids, creatinine/estimated glomerular filtration rate 
(eGFR), height and weight, smoking habits, eye exam-
ination, albuminuria, monofilament test); medication 
(antihyperglycemic, antihypertensive, antithrombotic 
and lipid-lowering therapy extracted from the GP’s 
electronic prescription files); intermediate outcomes 
(HbA1c, blood pressure, cholesterol, low-density lipo-
protein (LDL), creatinine/eGFR); and vascular compli-
cations (retinopathy, nephropathy (albuminuria, 
eGFR <60 mL/min/1.73 m2), neuropathy (pathological 
10 g monofilament test), foot ulcer, lower limb ampu-
tation, coronary heart disease (angina, myocardial 
infarction, percutaneous coronary intervention/coro-
nary artery bypass surgery), stroke (excluding transient 
ischemic attacks (TIA)), atrial fibrillation, and percu-
taneous transluminal angioplasty/arterial surgery). In 
the present study we included the last registered value 
in 2014 for most variables, except for eye examination, 
creatinine/eGFR and lipids (last registered 2012–2014), 
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and smoking habits (last registered 2010–2014) (online 
supplementary table S1). Medication was extracted from 
the GP’s electronic prescriptions the last 15 months, 
October 1, 2013 to December 31, 2014.
Of the 11 428 patients in the electronic patient records 
with diabetes, 10 248 had type 2 diabetes. Patients who 
did not have their main follow-up in general practice 
(residential patients in nursing homes (n=63), patients 
attending a specialist clinic >1 time/year (n=421), 
patients with a diabetes duration of less than 6 months 
and patients who had died or moved from the practice 
area during 2014 (n=300)), in total n=784 (8%), were 
excluded from the analysis, leaving 9464 patients with 
type 2 diabetes for statistical analysis (figure 1).
The ROSA 3 survey in 2005 used the same inclusion 
and exclusion criteria and methods of data extraction as 
ROSA 4,20 30 and consisted of a sample of 5463 patients 
with type 2 diabetes treated in primary care, from 60 
practices and 205 GPs (online supplementary figure 1). 
The ROSA 4 and ROSA 3 data sets used the same variable 
definition for almost all variables, except that the variable 
stroke excluded TIA in 2014, whereas TIA was included 
in 2005 (online supplementary table S1).
Quality of care was assessed against predefined review 
criteria based on key recommendations in the Norwe-
gian 2009 guidelines31: HbA1c ≤7.0% (53 mmol/mol), 
intervention threshold blood pressure >140/85 mm Hg 
with treatment target ≤135/80 mm Hg, and total choles-
terol ≤4.5 mmol/L. LDL targets were introduced with 
revision of the guidelines in 2009 but were not used in 
the comparison analyses due to missing data in the ROSA 
3 survey.
statistical analyses
We compared 2014 data with 2005 in regression models 
while controlling for patient age, gender and county of 
GP practice. We present average adjusted predictions 
with CIs adjusted for clustering within GP practices. 
Differences were tested for statistical significance using 
Wald tests. We did not control for diabetes duration 
since new patients may have been diagnosed at an earlier 
stage in the ROSA 4 study due to the introduction of 
HbA1c ≥6.5% (48 mmol/mol) as diagnostic criterion. 
All statistical analyses were performed using STATA/
SE V.14.0 for Windows, with functions logit, mlogit 
and regress, and with margins and test postestimation 
procedures. In consideration of the large sample size 
and correspondingly high statistical power, we applied a 
somewhat strict criterion (P≤0.01) for statistical signifi-
cance. In case of missing data, the percentages of valid 
cases and thus included cases are specified for each 
analysis.
In 2014, data were collected from two more coun-
ties than in 2005. We therefore performed a sensitivity 
analysis comparing data only from the three counties 
included in both ROSA 3 and 4. This analysis gave almost 
identical results for all variables (data not shown).
ResulTs
study samples
In 2014, 73% of GP practices agreed to participate 
compared with 91% in 2005. We included 9464 (2014) 
and 5463 (2005) patients with type 2 diabetes. Charac-
teristics of the study samples are presented in online 
supplementary table S2. There were more urban resi-
dents (85.2% vs 80.4%) and more men (54.6% vs 50.4%) 
included in 2014 compared with 2005, and the patients 
in 2014 also had a longer duration of diabetes (median 
duration 7 years vs 5 years). The samples were similar 
with regard to age, ethnicity, body mass index (BMI) 
and proportion of current smokers. The proportion 
of smokers was higher among patients <60 years vs ≥60 
years in both 2014 (29.7% vs 19.3%) and 2005 (33.8% vs 
20.4%).
Processes of care
HbA1c, blood pressure and cholesterol were measured 
in most patients (>85%) in both study years; however, 
HbA1c was performed in a lower proportion in 2014 
compared with 2005 (86.4% vs 91.8%, adjusted change 
−4.4 percentage points, P<0.001) (table 1).
Frequencies of measurement of LDL and creatinine/
eGRF were also high in 2014, with 84.4% and 93.2% of 
patients, respectively. Recording of both height/weight 
to estimate BMI was low in both study years (44.6% in 
2014), whereas registration of smoking habits increased 
(79.0% vs 56.0%, adjusted change +24.9 percentage 
points, P<0.001). Procedures related to screening for 
microvascular complications differed between 2014 
and 2005, with fewer patients undergoing eye exam-
ination in 2014 (61.0% vs 71.5%, adjusted change −7.1 
percentage points, P<0.001) and more patients under-
going the monofilament test (25.9% vs 18.7%, adjusted 
change +12.3 percentage points, P<0.001). Testing for 
albuminuria remained low (30.3%) in 2014.
medication
Hyperglycemia was controlled by diet alone in approxi-
mately one-third of the patients in both surveys (table 2).
There was shift away from insulin in monotherapy 
toward other therapy schemes between 2005 and 
2014 (P<0.001), and the overall frequency of the use 
of insulin also decreased (14.7% vs 22.2%, adjusted 
change −5.6 percentage points, P<0.001). Significantly 
more patients were on combination therapy involving 
more than two agents in 2014 (9.5% vs 1.8%, adjusted 
change +6.9 percentage points). Metformin was the most 
frequently used antihyperglycemic agent in 2014 (57.9%), 
and the use of metformin had increased substantially 
since 2005 (46.3%; adjusted change +9.6 percentage 
points, P<0.001). Use of sulfonylureas, on the other 
hand, was reduced (18.6% vs 30.7%, adjusted change 
−12.4 percentage points, P<0.001). New glucose-lowering 
agents were used by one-fifth of the patients in 2014.
Sixty-six per cent of the patients received antihy-
pertensive medication in both study years; however, 
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Change from 2005 to 2014 
with 95% CI‡
Percentage pointsObserved, with 95% CI† Adjusted‡  Observed Adjusted‡
HbA1c 86.4 (84.9 to 87.9) 86.8 91.8 91.3  −4.4 (−6.7 to −2.1)**
Blood pressure 87.4 (85.8 to 89.0) 88.1 89.7 88.7 −0.5 (−3.2 to 2.2)
Cholesterol 89.0 (86.8 to 91.2) 89.0 89.5 89.6 −0.6 (−3.7 to 2.4)
LDL 84.4 (81.1 to 87.7) 83.8 40.8 41.7  +42.1 (32.9 to 51.2)** 
Creatinine/eGFR 93.2 (91.5 to 95.0) NA
Weight 51.4 (46.7 to 56.1) 51.8 54.2 53.6 −1.8 (−12.7 to 9.1)
BMI 44.6 (40.0 to 49.3) 45.1 36.9 36.3 +8.8 (−1.9 to 19.5)
Smoking habits 79.0 (76.2 to 81.9) 79.6 56.0 54.6  +24.9 (18.3 to 31.5)**
Eye examination 61.0 (57.4 to 64.6) 62.3 71.5 69.4  −7.1 (−11.1 to −3.2)**
Albuminuria 30.3 (25.6 to 34.9) 31.3 37.9 36.1 −4.8 (−13.8 to 4.1)
Monofilament 10 g 25.9 (21.5 to 30.3) 28.1 18.7 15.8  +12.3 (6.6 to 17.9)** 
Number of screening 
procedures for microvascular 
complications§
**
  0 29.2 (25.7 to 32.8) 28.0 21.2 22.8 +5.2 (0.5 to 10.0)
  1 36.3 (34.2 to 41.6) 35.5 41.6 43.0 −7.5 (−11.7 to −3.4)
  2 22.5 (20.0 to 25.0) 23.0 25.7 24.6 −1.6 (−6.5 to 3.2)
  3 12.0 (9.1 to 14.8) 13.4 11.6 9.6 +3.9 (−0.8 to 8.6)
*P≤0.01, **P≤0.001. 
†Based on data as registered, 95% CIs adjusted for clustering within GP practices.
‡Adjusted for sex, age, counties and clustering within GP practices.
 §Screening procedures: eye examination, albuminuria and 10 g monofilament test.
BMI, body mass index; eGFR, estimated glomerular filtration rate; GP, general practitioner; HbA1c, hemoglobin A1c; LDL, low-density 
lipoprotein; NA, not available; ROSA 3, Rogaland-Oslo-Salten study; ROSA 4, Rogaland-Oslo-Salten-Akershus-Hordaland study.
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the use of ACE/AII inhibitors, calcium blockers and 
thiazides all increased (all P≤0.001). The proportion 
of patients on lipid-lowering medication increased 
among patients with coronary heart disease (77.9% 
vs 67.5%, adjusted change +8.8 percentage points, 
P<0.001) as well as in general (54.5% vs 43.7%, adjusted 
change +11.3 percentage points, P<0.001).
measurements and attained treatment targets
The patients achieved significantly more of the 2009 
national treatment targets in 2014 than in 2005 (P<0.001), 
even though only 16.1% of the patients reached all three 
targets in 2014 (table 3).
HbA1c ≤7.0% (≤53 mmol/mol) was achieved by 
62.8% in 2014 vs 54.3% of the patients in 2005 (adjusted 
change +8.0 percentage points, P<0.001), although the 
mean HbA1c levels declined by only 0.2 percentage 
points (1.6 mmol/mol) (adjusted; P<0.001). Among 
patients on diet only, a high proportion attained the 
HbA1c target in both study years (85.8% in 2014), and in 
2014 an improvement was seen among patients on medi-
cation (53.5% vs 43.7%, adjusted change +7.9 percentage 
points, P=0.001). The proportion with HbA1c >9.0% 
(>75 mmol/mol) was fairly stable (5.6% in 2014).
More patients met blood pressure targets 
(≤135/80 mm Hg on antihypertensive medication and 
≤140/85 mm Hg without medication) in 2014 (50.3% vs 
42.3%, adjusted change +7.2 percentage points, P=0.001), 
and the mean adjusted systolic blood pressure decreased 
by 3.3 mm Hg (P<0.001).
Substantially more patients also achieved the total 
cholesterol target (≤4.5 mmol/L) in 2014 (49.9% 
vs 33.5%, adjusted change +15.4 percentage points, 
P<0.001). Among patients on lipid-lowering medication, 
the proportions reaching target total cholesterol were 
in general higher and also increasing (65.3% vs 49.9%, 
adjusted change +13.7 percentage points, P<0.001). The 
2009 treatment target for LDL was met by 51.9% of all 
patients in 2014; however, among patients with coronary 
heart disease, the proportion with LDL ≤1.8 mmol/L was 
substantially lower: 29.7%.
Vascular complications
The proportion of patients with coronary heart disease 
was relatively stable (22.0% in 2014) (table 4).
There was a marked decrease in the proportion with 
neuropathy and with pathological monofilament test 
results among the relatively few patients registered 
5BMJ Open Diab Res Care 2017;5:e000459. doi:10.1136/bmjdrc-2017-000459
Table 2 Overview of antihyperglycemic, antihypertensive, lipid-lowering and antithrombotic therapy in patients with type 





Percentages Change from 2005 to 
2014 with 95% CI‡
Percentage points
Observed, with 95% 
CI† Adjusted‡ Observed Adjusted‡
Antihyperglycemic therapy**
  Diet only 31.7 (28.4 to 34.9) 32.5 28.2 27.0 +5.5 (1.0 to 10.1)
  Antihyperglycemic agents except for 
insulin
53.6 (50.8 to 56.5) 52.2 49.6 52.3 −0.1 (−4.2 to 4.1)
  Insulin only 5.4 (4.7 to 6.0) 5.6 12.4 11.6 −6.0 (−7.9 to −4.2)
  Insulin combined with other 
antihyperglycemic agents
9.3 (8.4 to 10.2) 9.7 9.7 9.1 +0.6 (−0.7 to 2.0)
Groups of antihyperglycemic agents
  Metformin 57.9 (54.7 to 61.1) 57.2 46.3 47.6  +9.6 (5.2 to 14.1)**
  Sulfonylurea 18.6 (17.0 to 20.3) 18.5 30.7 31.0  −12.4 (−15.7 to 
−9.1)**
  Insulin 14.7 (13.5 to 15.9) 15.3 22.2 20.9  −5.6 (−8.2 to −3.1)**
  DPP-4 inhibitors 13.9 (12.0 to 15.7) NA
  GLP1 analogs 2.6 (2.1 to 3.1) NA
  SGLT2 inhibitors 3.4 (2.5 to 4.4) NA
Numbers of antihyperglycemic agents, insulin included**
  1 36.2 (34.1 to 38.2) 36.0 43.8 44.4 −8.4 (−11.7 to −5.0)
  2 22.7 (21.3 to 24.0) 22.5 26.2 26.6 −4.2 (−6.6 to −1.7)
  ≥3 9.5 (8.5 to 10.5) 9.0 1.8 2.1 +6.9 (5.9 to 7.9)
Antihypertensive agents
Antihypertensives 65.9 (63.2 to 68.6) 65.9 66.4 66.4 −0.5 (−3.9 to 2.9)
  ACE/AII inhibitors 52.5 (50.1 to 54.8) 52.8 47.4 46.8 +6.0 (2.3 to 9.6)**
  Beta blockers 30.5 (28.6 to 32.3) 30.7 31.2 30.9 −0.3 (−3.0 to 2.5)
  Calcium blockers 25.9 (24.1 to 27.7) 26.6 22.2 21.2  +5.4 (2.9 to 7.9)**
  Thiazides 26.8 (25.1 to 28.6) 27.4 22.0 21.2  +6.2 (3.5 to 9.0)**
Number of antihypertensives**
  1 19.2 (18.2 to 20.2) 19.1 20.0 20.2 −1.1 (−2.9 to 0.8)
  2 20.3 (19.3 to 21.3) 20.2 19.5 19.6 0.6 (−1.2 to 2.4)
  3 16.4 (15.3 to 17.4) 16.5 14.5 14.3 +2.2 (0.6 to 3.8)
  ≥4 10.0 (8.9 to 11.1) 10.4 12.4 11.6 −1.1 (−3.1 to 0.8)
Lipid-lowering medication 54.5 (51.9 to 57.2) 54.7 43.7 43.4  +11.3 (7.1 to 15.5)**
  With coronary heart disease 77.9 (74.3 to 81.5) 77.3 67.5 68.5  +8.8 (3.4 to 14.2)**
Antithrombotic therapy 36.9 (34.7 to 39.2) 37.3 40.3 39.7 −2.5 (−6.0 to 1.1)
Medication was extracted from the GP’s electronic prescriptions. For antithrombotic therapy 0.6% (n=33) were missing in 2005, and for all 
other medication groups data were available in 100% of the cases.
*P≤0.01, **P≤0.001.
†Based on data as registered, 95% CIs adjusted for clustering within GP practices.
‡Adjusted for sex, age, counties and clustering within GP practices.
DPP-4, Dipeptidyl peptidase-4; GLP1, Glucagon-like peptide-1; NA, not available; ROSA 3, Rogaland-Oslo-Salten study; ROSA 4, Rogaland-
Oslo-Salten-Akershus-Hordaland study; SGLT2, Sodium-glucose co-transporter-2.
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with these variables. Chronic kidney disease as evalu-
ated by eGFR <60 mL/min was present in 17.3% of the 
patients in 2014, whereas 1.7% had eGFR of less than 
30 mL/min.
dIsCussIOn
We found clinically important improvements in the 
percentages attaining recommended targets for HbA1c, 
blood pressure and lipids in 2014 vs 2005. However, the 















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































recording of screening procedures for microvascular 
complications remained alarmingly poor. Furthermore, 
the proportion of current smokers was disturbingly 
high.
study samples
We consider our findings to be representative for patients 
with type 2 diabetes treated by GPs in Norway. In both the 
ROSA 4 and ROSA 3 surveys, data were collected from 
routine clinical practice, with all GPs in a practice partic-
ipating. Furthermore, patients in the 2014 survey were 
similar to the type 2 diabetes population in the compre-
hensive Swedish and Scottish diabetes registries in 2014 
and with other recently published surveys from Europe 
and the USA with respect to age, gender, diabetes dura-
tion and BMI.9 14 15 18 32–35
Processes of care
Recordings of HbA1c, blood pressure, lipids and 
smoking status in 2014 were acceptable and comparable 
to other surveys, while recording of weight/BMI was 
low.14 15 36 Screening for microvascular complications was 
poor and inferior to that found in the diabetes registries 
from Sweden and Scotland, in the UK National Diabetes 
Audit and in cross-sectional studies in the USA.14–16 36 
When comparing the results from ROSA 4 with Sweden, 
Scotland, UK and the USA, the proportions with annual 
checks for albuminuria were 30% vs 73%–75%, neurop-
athy 26% vs 71%–94%, and eye examination 61% vs 
70%–90%. Surprisingly, the percentage of patients with 
a recorded ophthalmological examination was lower 
in 2014 than in 2005. The differences between Norway 
and Sweden may be due to the use of reminders on the 
fill-in forms used by practices to report to the registry and 
the availability of diabetes specialist nurses in GP prac-
tices in Sweden. In addition, national initiatives in the 
UK to improve care for people with diabetes may have 
led to increasing screening rates, that is, the National 
Service Framework for Diabetes.37 In pediatric diabetes 
care in Norway, it has been shown that establishment of 
a nationwide system for benchmarking of quality indica-
tors resulted in significant improvements in risk factor 
control and screening assessments.38
In the general population in Norway, the percentage 
of current smokers decreased from 24% in 2004 to 
13% in 2014.39 In contrast the prevalence of current 
smokers in ROSA 4 remained high (22.0%) and similar 
to reports from the American National Health and 
Nutrition Examination Survey (NHANES), where 
the prevalence remained unchanged at 22% between 
1999–2002 and 2007–2010.16 Corresponding percent-
ages in Sweden and Scotland in 2014 were 15% and 
18%.14 15 A Swedish study found an excess mortality in 
patients with type 2 diabetes younger than 55 years, 
and 38% of these were current smokers.9 Motivating 
patients with diabetes to stop smoking should be an 
important priority for GPs.
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medication, measurements and attained treatment targets
In accordance with national guidelines, the percentage 
of patients using metformin increased. The use of sulfon-
ylureas decreased substantially (−12 percentage points). 
The same trends were seen in a recent publication from 
the USA.35
Risk factor control has improved during the last 
decade. The increase in achievement of HbA1c targets 
was similar to the observations between the periods 
1999–2002 and 2007–2010 in NHANES (+8 percentage 
points).16 Compared with recent cross-sectional studies 
or annual reports from diabetes registries of type 2 
diabetes in general practice worldwide, the proportion 
of patients achieving HbA1c <7.0% (<53 mmol/mol) in 
ROSA 4 was 57% vs 47%–52%.15 16 18 19 This confirms that 
glycemic control in Norwegian general practice is similar 
to other countries. We only found a slight improvement in 
mean HbA1c that was similar to findings in reports from 
the Swedish Diabetes Registry and NHANES.14 16 The 
decrease in mean HbA1c was only 0.2 percentage points 
(1.6 mmol/mol) despite the fact that antihyperglycemic 
drug expenditures increased by 60%. The relatively small 
decline in mean HbA1c seen during the last decade may 
be due to the reduction of the use of insulin. It is possible 
that the GPs postpone insulin treatment, and start with 
the new expensive antihyperglycemic agents, which have 
less glucose-lowering effect than insulin. During recent 
years guidelines have emphasized the need for individual 
glycemic treatment targets for patients with long diabetes 
duration and comorbidities.27–29 These targets are often 
less intensive than previously strict recommendations 
and may also explain the clinically insignificant change 
in mean HbA1c. Finally, mean HbA1c is now at such a 
low level that lower mean values are difficult to achieve in 
large study populations.
There was no significant decrease in BMI in 2014 
compared with 2005 despite the introduction of 
weight-neutral and weight-reducing therapies. However, 
the proportion of patients on such therapies was rela-
tively low in 2014 (Dipeptidyl peptidase 4 (DPP4) inhib-
itors 13.9%, Sodium-glucose co-transporter-2 (SGLT2) 
inhibitors, 3.4%, Glucagon-like peptide-1 (GLP1) analogs 
2.6%).
The increased use of ACE/II inhibitors, calcium 
blockers and thiazides probably explains the improved 
blood pressure control. However, there is still a high 
proportion of untreated patients above intervention 
threshold and treated patients above blood pressure 
targets. In our present study 38.5% achieved a blood 
pressure ≤130/80 mm Hg (regardless of medication) in 
2014. Findings from other countries span from 33.8% 
(Scotland) and 41.6% (Swedish Diabetes Registry), to 
51.3% (NHANES).15 16 19
The improved control of dyslipidemia might be influ-
enced by the introduction of LDL targets in national 
guidelines in 2009.31 The proportion of patients on 
lipid-lowering therapy with cholesterol <4.5 mmol/L was 
similar in ROSA 4 and the Swedish Diabetes Registry 
(62.0% vs 59.0%), while the Swedish had a higher propor-
tion with LDL <2.5 mmol/L (42.3% vs 52.6%). The use 
of statins in ROSA 4 was inferior to Sweden (54.5% vs 
63.7%). Only 28.5% of patients with a history of CVD 
attained LDL target ≤1.8 mmol/L, similar to results from 
NHANES (27.5%).16 This indicates that more patients 
with diabetes should start lipid-lowering therapy in 
Norway and that GPs should maintain efforts to achieve 
the strict LDL target in high-risk persons with CVD.
Vascular complications
There was no significant change in the prevalence of 
coronary heart disease during the last decade in our 
study populations. This is similar to the findings in 
two recent cross-sectional surveys from the USA.33 35 
The prevalence of microvascular complications in our 
study is subject to uncertainty due to poor recording 
of screening among GPs in both surveys (~60% eye 
examination, ~30% albuminuria test and ~25% mono-
filament test in 2014). We found no significant change 
in retinopathy between ROSA 4 and ROSA 3, but 
the 12.3% prevalence of patients with retinopathy in 
2014 is probably underestimated due to inconsistent 
reporting. The Swedish Adult Diabetes Register 
reports a prevalence of retinopathy of 29.6% in their 
annual 2014 report. Their findings are probably more 
representative of retinopathy among patients with type 
2 diabetes in general practice in Scandinavia.14 Fewer 
persons had neuropathy in ROSA 4 compared with 
ROSA 3, while more patients had a recorded mono-
filament test. The finding may be explained by selec-
tion bias if GPs in 2005 used monofilament test more 
frequently in patients suspected of having neuropathy. 
The prevalence of neuropathy in 2014 (18.8%) is in 
agreement with reports from the Swedish National 
Diabetes Register 2014 (21%), and both countries 
have ~2.7% with a history of foot ulcer. ROSA 4 and 
Scotland report similar percentages of lower limb 
amputation (0.6% and 0.7%, respectively). ROSA 4 
and Scotland have the same proportion of patients 
with end-stage renal failure (0.6%).
strengths and weaknesses
This study is one of the largest representative cross-sec-
tional studies of type 2 diabetes in general practice 
performed in recent years, originating from a high-in-
come country with an apparently well-organized health-
care system. Our study has some limitations. Screening 
procedures for microvascular complications are based 
on recorded data in the case notes. If GPs fail to record 
performed procedures, our results will overestimate the 
quality gaps. The level of albuminuria is not reported 
due to different measurement methods/units between 
GP practices, and frequent missing data. Finally, we 
excluded patients with main-follow up in specialist 
healthcare who probably had worse glycemic control; 
however, the absolute numbers were small and unlikely 
to influence the results (4.4% in 2014 vs 5.0% in 2005).
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In summary, we found moderate improvements 
in blood pressure and lipid control during the last 
decade, which are similar to improvements reported 
from other countries. Improvements during the last 
decade are less striking than improvements reported in 
the previous decade. We demonstrated that there are 
still major gaps in the performance of recommended 
screening procedures to detect microvascular compli-
cations. Clinical performance in this area was consid-
erably worse than other comparable countries. We 
also found a disturbingly high proportion of current 
smokers diverging from trends seen in the general 
Norwegian population. There is still considerable 
room for improvements of many aspects of diabetes 
care in general practice. Screening for microvascular 
complications must be improved. Risk factor control, 
especially the treatment of dyslipidemia, and the 
promotion of smoking cessation require attention. We 
suggest compulsory reporting to a national diabetes 
register and feedback to GPs as a means of continu-
ally evaluating diabetes control and promoting further 
improvements in diabetes care in Norway. A national 
screening program for diabetes retinopathy should also 
be considered.
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